Ensysce Biosciences, Inc. cash flow to debt ratio of -2.55K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Ensysce Biosciences, Inc.'s free cash flow has decreased 4.05% from $-7.50T last year to $-7.81T, signaling decreasing performance

Ensysce Biosciences, Inc.'s debt to equity ratio is -0.72, signaling that the company spent its equity and risk bankruptcy.

Ensysce Biosciences, Inc.'s debt to equity ratio is -0.72, signaling that the company spent its equity and risk bankruptcy.

Ensysce Biosciences, Inc. has negative EBITDA, making leverage ratio unreliable

Ensysce Biosciences, Inc.'s interest coverage ratio is -628.42, which means that the company struggles to meet interest obligations, signaling financial risk.

Ensysce Biosciences, Inc.'s profit margin has decreased (428.74%) in the last year from -153.30% to -810.57%, signaling decreasing performance

Ensysce Biosciences, Inc.'s short-term assets of $7.24M exceed its short-term liabilities of $4.57M

Ensysce Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Ensysce Biosciences, Inc.'s return on equity of -631.47%, is lower than 15.00%, indicating bad performance

Ensysce Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Ensysce Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Ensysce Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Ensysce Biosciences, Inc. has negative free cash flow, indicating cash burn

Ensysce Biosciences, Inc.'s yearly earnings has decreased 27.40% since last year from $-7.99M to $-10.18M, signaling decreasing performance

Ensysce Biosciences, Inc.'s yearly revenue has decreased 100.00% since last year from $5.21M to $0.00, signaling decreasing performance

ROIC 2.80K% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Ensysce Biosciences, Inc.'s 3-year revenue CAGR of 26.16% is positive, indicating growing revenue over the past 3 years

Ensysce Biosciences, Inc. had revenue growth in only 1 out of 5 years, indicating inconsistent revenue performance

Ensysce Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Ensysce Biosciences, Inc. is undervalued relative to its fair value price of 396.70K based on Discounted Cash Flow model

Ensysce Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ensysce Biosciences, Inc. is undervalued relative to its fair value price of 431.52K based on EBITDA multiple model

Ensysce Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Ensysce Biosciences, Inc. has insufficient data to evaluate this check.

Ensysce Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Ensysce Biosciences, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Ensysce Biosciences, Inc. has a price-to-sales ratio of 2.02x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue